Gagan Fervaha1, Ofer Agid2, George Foussias3, Gary Remington3. 1. Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Canada; Institute of Medical Science, University of Toronto, Toronto, Canada. Electronic address: gagan.fervaha@utoronto.ca. 2. Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada. 3. Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Canada; Institute of Medical Science, University of Toronto, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada.
Abstract
BACKGROUND: Many individuals with schizophrenia experience a profound deficit in global cognitive ability, which is related to poor functional outcomes. Historically, the standard of assessing neurocognitive impairments is one of extensive neuropsychological batteries that are labour-intensive. The present study examined whether a brief neurocognitive assessment (BNA) instrument could effectively estimate global neurocognition and further examined its clinical utility. METHODS: The validity and clinical utility of a BNA that takes approximately 10 min to administer was examined against a full neuropsychological battery that takes approximately 90 min to administer in a large and heterogeneous sample of 1303 patients with schizophrenia. RESULTS: The BNA explained 76% of the variance in global neurocognition in the total sample and remained consistent in subsamples stratified by clinical characteristics (e.g., severity of psychopathology) and in randomized re-sampling simulations. The two items that comprised the BNA were the letter-number sequencing test, a measure of working memory, and the digit-symbol test, a measure of processing speed. Next, perhaps more importantly, the BNA and full neuropsychological battery were related to symptoms and functional status to a similar degree in both univariate and multivariate regression models; moreover, both instruments were sensitive to longitudinal treatment related change to a similar degree. CONCLUSIONS: The BNA is able to rapidly, easily, and validly assess global neurocognition in schizophrenia. The BNA was associated with important clinical outcomes to a similar degree as a full cognitive battery. This tool provides clinicians and researchers a means to assess global neurocognitive impairments without requiring extensive neuropsychological testing.
BACKGROUND: Many individuals with schizophrenia experience a profound deficit in global cognitive ability, which is related to poor functional outcomes. Historically, the standard of assessing neurocognitive impairments is one of extensive neuropsychological batteries that are labour-intensive. The present study examined whether a brief neurocognitive assessment (BNA) instrument could effectively estimate global neurocognition and further examined its clinical utility. METHODS: The validity and clinical utility of a BNA that takes approximately 10 min to administer was examined against a full neuropsychological battery that takes approximately 90 min to administer in a large and heterogeneous sample of 1303 patients with schizophrenia. RESULTS: The BNA explained 76% of the variance in global neurocognition in the total sample and remained consistent in subsamples stratified by clinical characteristics (e.g., severity of psychopathology) and in randomized re-sampling simulations. The two items that comprised the BNA were the letter-number sequencing test, a measure of working memory, and the digit-symbol test, a measure of processing speed. Next, perhaps more importantly, the BNA and full neuropsychological battery were related to symptoms and functional status to a similar degree in both univariate and multivariate regression models; moreover, both instruments were sensitive to longitudinal treatment related change to a similar degree. CONCLUSIONS: The BNA is able to rapidly, easily, and validly assess global neurocognition in schizophrenia. The BNA was associated with important clinical outcomes to a similar degree as a full cognitive battery. This tool provides clinicians and researchers a means to assess global neurocognitive impairments without requiring extensive neuropsychological testing.
Authors: Matthias N Hartmann-Riemer; Steffen Aschenbrenner; Magdalena Bossert; Celina Westermann; Erich Seifritz; Philippe N Tobler; Matthias Weisbrod; Stefan Kaiser Journal: Sci Rep Date: 2017-01-10 Impact factor: 4.379
Authors: Lauren Luther; Benjamin E Buck; Melanie A Fischer; Annalee V Johnson-Kwochka; George Coffin; Michelle P Salyers Journal: J Technol Behav Sci Date: 2020-08-31
Authors: Steven G Potkin; Jean-Yves Loze; Carlos Forray; Ross A Baker; Christophe Sapin; Timothy Peters-Strickland; Maud Beillat; Anna-Greta Nylander; Peter Hertel; Simon Nitschky Schmidt; Anna Eramo; Karina Hansen; Dieter Naber Journal: Int J Neuropsychopharmacol Date: 2017-01-01 Impact factor: 5.176
Authors: Richard S E Keefe; George M Haig; Stephen R Marder; Philip D Harvey; Eduardo Dunayevich; Alice Medalia; Michael Davidson; Ilise Lombardo; Christopher R Bowie; Robert W Buchanan; Dragana Bugarski-Kirola; William T Carpenter; John T Csernansky; Pedro L Dago; Dante M Durand; Frederick J Frese; Donald C Goff; James M Gold; Christine I Hooker; Alex Kopelowicz; Antony Loebel; Susan R McGurk; Lewis A Opler; Amy E Pinkham; Robert G Stern Journal: Schizophr Bull Date: 2015-09-11 Impact factor: 9.306
Authors: Susana Da Silva; Areti Apatsidou; Sarah Saperia; Ishraq Siddiqui; Eliyas Jeffay; Aristotle N Voineskos; Zafiris J Daskalakis; Gary Remington; Konstantine K Zakzanis; George Foussias Journal: Front Psychiatry Date: 2018-05-11 Impact factor: 4.157
Authors: Lauren Luther; Kelsey A Bonfils; Melanie W Fischer; Annalee V Johnson-Kwochka; Michelle P Salyers Journal: Schizophr Res Cogn Date: 2019-04-17